Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with John Sims, MD. [LISTEN TIME: 17 minutes]
John Sims, MD
Advertisement
Articles by John Sims, MD
The head of medical development for donanemab at Eli Lilly and Company explained how donanemab’s modified titration dosing regimen could reduce ARIA risk and improve clinical decision-making following the drug’s FDA label update. [WATCH TIME: 3 minutes]
The head of medical development for donanemab at Eli Lilly and Company provided insights on the structure of TRAILBLAZER-ALZ 6, a study comparing numerous different dosing regimens of donanemab. [WATCH TIME: 3 minutes]
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-MTBR Tau Antibody Etalanetug Given FDA Fast Track Designation
2
Incidence and Prevalence of Frontotemporal Dementia Similar to Dementia with Lewy Bodies, Meta-Analysis Shows
3
Smartphone-Based App for Muscular Relaxation Significantly Reduces Migraine-Related Disability in Emergency Room Settings
4
NeurologyLive® Friday 5 — October 24, 2025
5
